Osteoarthritis (OA) is characterized by cartilage degeneration and synovial inflammation, with chondrocytes playing a pivotal role in this disease. However, inflammatory mediators, mechanical stress, and oxidative stress can compromise functionality. The occurrence and progression of OA are intrinsically linked to the immune response. Current research on the treatment of OA mainly concentrates on the synergistic application of drugs and tissue engineering. The surface of engineered hydrogel materials can be immunomodified to affect the function of chondrocytes in drug therapy, gene therapy, and cell therapy. Prior studies have concentrated on the drug-loading function of hydrogels but overlooked the immunomodulatory role of chondrocytes. These modifications can inhibit the proliferation and differentiation of chondrocytes, reduce the inflammatory response, and promote cartilage regeneration. The surface immunomodification of engineered hydrogel materials can significantly enhance their efficacy in the treatment of OA. Thus, immunomodulatory tissue engineering has significant potential for treating osteoarthritis.

Osteosarcoma (OS) is a primary bone malignancy; however, its exact mechanism of development remains largely unknown. Recent studies have shown that miR-381

This study aimed to compare surgical antibiotic prophylaxis (SAP) practices among patients undergoing total joint arthroplasty (TJA) under two different mo

Osteosarcoma (OS) is a prevalent and aggressive primary carcinoma of the bone that predominantly influences children and adolescents. Inadequate therapeuti